CD274 and neoplasm: The spectrum of advanced malignancies in which the use of mAbs targeting PD‐1 or PD‐L1 is indicated has broadened, including non‐small lung cancer, melanoma, urothelial tumors, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, gastric tumor and so forth.108 Despite the unprecedented success in tumor therapy, a large number of tumor patients still do not benefit from this class of agents.